# Orano Med

Source: https://onco.cc/companies/orano-med/  
OnCo record `orano-med` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Orano Med is the leading lead-212 producer and the developer of 212Pb-DOTAMTATE (AlphaMedix).

## Summary

Orano Med, based in Paris and Plano, Texas, is the leading producer of lead-212 and the developer of 212Pb-DOTAMTATE, known as AlphaMedix, an alpha-emitting radioligand for somatostatin-receptor-positive neuroendocrine tumours. AlphaMedix reported a 56 percent objective response rate in its phase 2, the company builds lead-212 generators, and it works with Sanofi and RadioMedix. OnCo links it to neuroendocrine tumours, to somatostatin receptor 2 as a target, to peptide receptor radionuclide therapy, targeted alpha therapy and the isotope supply chain, and to the idea of funding alpha emitters beyond actinium-225, including lead-212, terbium-149 and astatine-211. Manufacturing cost and time for radioactive medicines is the bottleneck it sits inside. Whether lead-212 can be delivered to enough hospitals to matter is the open question.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Paris / Plano, TX
- Type: radiopharma
- Website: https://www.oranomed.com

## Sources

- Official website: https://www.oranomed.com

## Connected records

- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- targets: [Somatostatin receptor 2](https://onco.cc/targets/sstr2/)
- trials: [ALPHAMEDIX-02](https://onco.cc/trials/alphamedix-02/), [Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors](https://onco.cc/trials/nct07278479/)
- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- technologies: [Actinium-225 supply: thorium stocks, accelerators and radium targets](https://onco.cc/technologies/actinium-225-supply/), [Peptide receptor radionuclide therapy (PRRT)](https://onco.cc/technologies/prrt/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/), [Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)](https://onco.cc/technologies/therapy-isotope-supply-chain/)
- drugs: [212Pb-DOTAMTATE](https://onco.cc/drugs/alphamedix/)
- companies: [RadioMedix](https://onco.cc/companies/radiomedix/)
- roadmaps: [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://onco.cc/roadmaps/radiopharma-roadmap/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)
- ideas: [Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211](https://onco.cc/ideas/idea-reg-alpha-emitter-portfolio/), [Recover legacy radium-226 sources worldwide as the feedstock for actinium-225](https://onco.cc/ideas/idea-reg-legacy-radium-recovery-ac225/)

---
JSON: https://onco.cc/api/v1/entities/orano-med.json